#United States #Boston #GE HealthCare #Fuse Oncology #S!GNAL

Fuse Oncology to Present at ASTRO 2026

Fuse Oncology has officially announced its participation in the upcoming ASTRO 2026 Annual Meeting, scheduled for September 27 to 29 in Boston. During this prestigious event, the company will unveil a potential workflow experience that integrates GE HealthCare's Intelligent Radiation Therapy™ (iRT) software solution with S!GNAL, its innovative charge capture tool.

The presentation will demonstrate how the iRT software can effectively launch S!GNAL directly from patient workflows, using pertinent patient data. This direct connection aims to streamline the path from workflow coordination in iRT to targeted charge reviews in S!GNAL, thereby minimizing manual input and preserving the patient's context.

In the realm of radiation oncology, teams often navigate between various disconnected systems—such as electronic medical records (EMR), oncology information systems (OIS), and treatment planning software. The introduction of iRT, an AI-driven software solution, is designed to improve this situation by connecting various tools and reducing unnecessary manual handoffs. Its goal is to help facilitate a smoother transition for patients from diagnosis through to treatment.

The integration of S!GNAL into this workflow promises to address critical issues associated with charge capture in radiation oncology. Mistakes such as missing images or untagged physics consultations frequently arise but often remain undiscovered for weeks, causing significant delays and complications. By contrast, S!GNAL actively reviews charge data on a daily basis, flagging any missed or miscoded charges within just 24 hours following service delivery. This immediate identification is a significant improvement over the retrospective audits that typically take place weeks later.

S!GNAL’s rule logic encompasses all relevant categories of radiation oncology codes, particularly focusing on high-impact items such as treatment fractions and dosimetry planning. It evaluates planning charges against actual data from the treatment planning system as opposed to relying solely on document titles or template assumptions. Furthermore, S!GNAL's onboarding process is designed to be efficient; it can be installed once and then configured to meet the specific rules applicable to each site within a multi-site organization.

In a recent deployment for an 18-site radiation oncology network, S!GNAL was able to uncover over $1 million in missed charges for treatment delivery and IGRT services between July 2024 and March 2025. This capability not only highlighted issues promptly but also considerably reduced the time gap between service delivery and charge documentation by over 30 days.

James Bauler, CEO of Fuse Oncology, emphasized the challenges faced by clinics in handling charge capture effectively, stating, "Every clinic we talk to has the same problem, and almost none of them have the staff to solve it by auditing harder. The fix is to put detection where the work already happens, in a system the team is already using. Every hour spent chasing past data detracts from the time that could be focused on patient treatment."

The potential workflow experience between iRT and S!GNAL is currently in development and evaluation stages, with its commercial availability expected in the future. Attendees at the ASTRO 2026 exhibition can visit Fuse Oncology at booth 2533 for further insights into this integration and its potential benefits for radiation oncology workflows.

About Fuse Oncology

Fuse Oncology is a pioneering healthcare technology firm specializing in radiation oncology. The company is dedicated to enhancing clinical and administrative workflows through its software as a service (SaaS) solutions, which aim to dissolve information silos in healthcare for a more fluid experience for clinicians and patients alike. With a focus on placing electronic medical records systems at the core of operational processes, Fuse strives to accelerate oncology care delivery. More information can be found at FuseOnc.com. Make sure to follow them on LinkedIn @fuseoncology to keep up with their latest updates.